{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T04:00:30Z","timestamp":1785124830795,"version":"3.55.0"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":65,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-53503-6","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T20:03:01Z","timestamp":1779307381000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bioinformatics and experimental validation of druggable targets in non-alcoholic fatty liver disease"],"prefix":"10.1038","volume":"16","author":[{"given":"Xiangqian","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanyang","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuling","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"issue":"10290","key":"53503_CR1","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","volume":"397","author":"EE Powell","year":"2021","unstructured":"Powell, E. E., Wong, V. W. S. & Rinella, M. Non-alcoholic fatty liver disease. Lancet 397 (10290), 2212\u20132224 (2021).","journal-title":"Lancet"},{"issue":"5","key":"53503_CR2","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1002\/cld.1061","volume":"17","author":"S Cheemerla","year":"2021","unstructured":"Cheemerla, S. & Balakrishnan, M. Global epidemiology of chronic liver disease. Clin. Liver Dis. 17(5), 365\u201370 (2021).","journal-title":"Clin. Liver Dis."},{"issue":"8","key":"53503_CR3","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1016\/j.cgh.2023.04.015","volume":"21","author":"ZM Younossi","year":"2023","unstructured":"Younossi, Z. M., Wong, G., Anstee, Q. M. & Henry, L. The global burden of liver disease. Clin. Gastroenterol. Hepatol. 21(8), 1978\u201391 (2023).","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"2","key":"53503_CR4","doi-asserted-by":"publisher","first-page":"120","DOI":"10.2174\/0113892029280454240214072212","volume":"25","author":"A Mahmoudi","year":"2024","unstructured":"Mahmoudi, A., Hajihasani, M. M., Majeed, M., Jamialahmadi, T. & Sahebkar, A. Effect of Calebin-A on critical genes related to NAFLD: A protein-protein interaction network and molecular docking study. Curr. Genomics 25(2), 120\u201339 (2024).","journal-title":"Curr. Genomics"},{"issue":"3","key":"53503_CR5","doi-asserted-by":"publisher","first-page":"194","DOI":"10.32074\/1591-951X-242","volume":"113","author":"I Cataldo","year":"2021","unstructured":"Cataldo, I. et al. Pathology of non-alcoholic fatty liver disease. Pathologica 113 (3), 194 (2021).","journal-title":"Pathologica"},{"issue":"4","key":"53503_CR6","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1007\/s12072-015-9679-0","volume":"10","author":"B Mohamad","year":"2016","unstructured":"Mohamad, B. et al. Characterization of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) patients without cirrhosis. Hep. Intl. 10 (4), 632\u2013639 (2016).","journal-title":"Hep. Intl."},{"issue":"1","key":"53503_CR7","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/hep.32542","volume":"77","author":"PA Shah","year":"2023","unstructured":"Shah, P. A., Patil, R. & Harrison, S. A. NAFLD-related hepatocellular carcinoma: The growing challenge. Hepatology 77 (1), 323\u2013338 (2023).","journal-title":"Hepatology"},{"issue":"3","key":"53503_CR8","doi-asserted-by":"publisher","first-page":"225","DOI":"10.2174\/0113892029313473240919105819","volume":"26","author":"X He","year":"2025","unstructured":"He, X. et al. CDT1 is a potential therapeutic target for the progression of NAFLD to HCC and the exacerbation of cancer. Curr. Genomics 26(3), 225\u201343 (2025).","journal-title":"Curr. Genomics"},{"issue":"4","key":"53503_CR9","doi-asserted-by":"publisher","first-page":"290","DOI":"10.2174\/0109298665301698240404061300","volume":"31","author":"M Sotoudeheian","year":"2024","unstructured":"Sotoudeheian, M. Galectin-3 and severity of liver fibrosis in metabolic dysfunction-associated fatty liver disease. Protein Pept. Lett. 31 (4), 290\u2013304 (2024).","journal-title":"Protein Pept. Lett."},{"key":"53503_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.metop.2021.100149","volume":"12","author":"P Zarghamravanbakhsh","year":"2021","unstructured":"Zarghamravanbakhsh, P., Frenkel, M. & Poretsky, L. Metabolic causes and consequences of nonalcoholic fatty liver disease (NAFLD). Metab. Open 12, 100149 (2021).","journal-title":"Metab. Open"},{"issue":"4","key":"53503_CR11","doi-asserted-by":"publisher","first-page":"614","DOI":"10.3390\/diagnostics13040614","volume":"13","author":"F Radu","year":"2023","unstructured":"Radu, F. et al. The link between NAFLD and metabolic syndrome. Diagnostics 13 (4), 614 (2023).","journal-title":"Diagnostics"},{"issue":"1","key":"53503_CR12","first-page":"E18761429259143","volume":"17","author":"Y Xu","year":"2024","unstructured":"Xu, Y. et al. Dual role of pregnane X receptor in nonalcoholic fatty liver disease. Curr. Mol. Pharmacol. 17 (1), E18761429259143 (2024).","journal-title":"Curr. Mol. Pharmacol."},{"issue":"39","key":"53503_CR13","doi-asserted-by":"publisher","first-page":"11053","DOI":"10.3748\/wjg.v21.i39.11053","volume":"21","author":"L Marino","year":"2015","unstructured":"Marino, L. & Jornayvaz, F. R. Endocrine causes of nonalcoholic fatty liver disease. World J. Gastroenterol. WJG 21(39), 11053 (2015).","journal-title":"World J. Gastroenterol. WJG"},{"issue":"8","key":"53503_CR14","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/j.cgh.2012.03.011","volume":"10","author":"DM Torres","year":"2012","unstructured":"Torres, D. M., Williams, C. D. & Harrison, S. A. Features, diagnosis, and treatment of nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 10 (8), 837\u2013858 (2012).","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"2","key":"53503_CR15","doi-asserted-by":"publisher","first-page":"184","DOI":"10.3390\/biomedicines9020184","volume":"9","author":"D Ramai","year":"2021","unstructured":"Ramai, D. et al. Natural progression of non-alcoholic steatohepatitis to hepatocellular carcinoma. Biomedicines 9 (2), 184 (2021).","journal-title":"Biomedicines"},{"issue":"1","key":"53503_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3748\/wjg.v27.i1.1","volume":"27","author":"DG Buyco","year":"2021","unstructured":"Buyco, D. G. et al. Experimental models of metabolic and alcoholic fatty liver disease. World J. Gastroenterol. 27(1), 1 (2021).","journal-title":"World J. Gastroenterol."},{"issue":"3","key":"53503_CR17","doi-asserted-by":"publisher","first-page":"245","DOI":"10.7861\/clinmedicine.18-3-245","volume":"18","author":"J Maurice","year":"2018","unstructured":"Maurice, J. & Manousou, P. Non-alcoholic fatty liver disease. Clin. Med. 18 (3), 245\u2013250 (2018).","journal-title":"Clin. Med."},{"issue":"2","key":"53503_CR18","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1136\/gutjnl-2023-331740","volume":"74","author":"S Ghosh","year":"2025","unstructured":"Ghosh, S., Zhao, X., Alim, M., Brudno, M. & Bhat, M. Artificial intelligence applied to \u2019omics data in liver disease: Towards a personalised approach for diagnosis, prognosis and treatment. Gut 74(2), 295\u2013311 (2025).","journal-title":"Gut"},{"issue":"3","key":"53503_CR19","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.jhep.2014.10.036","volume":"62","author":"A Teufel","year":"2015","unstructured":"Teufel, A. Bioinformatics and database resources in hepatology. J Hepatol 62(3), 712\u20139 (2015).","journal-title":"J Hepatol"},{"issue":"1","key":"53503_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-18705-z","volume":"8","author":"J Li","year":"2018","unstructured":"Li, J. et al. Application of weighted gene co-expression network analysis for data from paired design. Scientific reports 8(1), 622 (2018).","journal-title":"Scientific reports"},{"issue":"11","key":"53503_CR21","first-page":"1791","volume":"33","author":"W Liu","year":"2017","unstructured":"Liu, W., Li, L., Ye, H. & Tu, W. Weighted gene co-expression network analysis in biomedicine research. Sheng wu gong cheng xue bao= Chinese journal of biotechnology 33(11), 1791\u2013801 (2017).","journal-title":"Sheng wu gong cheng xue bao= Chinese journal of biotechnology"},{"key":"53503_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fbinf.2022.958378","volume":"2","author":"CJ Radoux","year":"2022","unstructured":"Radoux, C. J., Vianello, F., McGreig, J., Desai, N. & Bradley, A. R. The druggable genome: Twenty years later. Frontiers in Bioinformatics 2, 958378 (2022).","journal-title":"Frontiers in Bioinformatics"},{"issue":"D1","key":"53503_CR23","doi-asserted-by":"publisher","first-page":"D1144","DOI":"10.1093\/nar\/gkaa1084","volume":"49","author":"SL Freshour","year":"2021","unstructured":"Freshour, S. L. et al. Integration of the Drug\u2013Gene Interaction Database (DGIdb 4.0) with open crowdsource efforts. Nucleic acids research 49(D1), D1144\u2013D51 (2021).","journal-title":"Nucleic acids research"},{"key":"53503_CR24","doi-asserted-by":"crossref","unstructured":"Finan, C. et al. The druggable genome and support for target identification and validation in drug development. Sci. Transl. Med. 9(383), 1\u201334 (2017).","DOI":"10.1126\/scitranslmed.aag1166"},{"issue":"D1","key":"53503_CR25","doi-asserted-by":"publisher","first-page":"D672","DOI":"10.1093\/nar\/gkae909","volume":"53","author":"M Kanehisa","year":"2025","unstructured":"Kanehisa, M., Furumichi, M., Sato, Y., Matsuura, Y. & Ishiguro-Watanabe, M. KEGG: Biological systems database as a model of the real world. Nucleic Acids Res. 53(D1), D672\u2013D7 (2025).","journal-title":"Nucleic Acids Res."},{"issue":"2","key":"53503_CR26","doi-asserted-by":"publisher","first-page":"270","DOI":"10.3390\/antiox10020270","volume":"10","author":"L Rinaldi","year":"2021","unstructured":"Rinaldi, L. et al. Mechanisms of non-alcoholic fatty liver disease in the metabolic syndrome. A narrative review. Antioxidants 10 (2), 270 (2021).","journal-title":"Antioxidants"},{"issue":"2","key":"53503_CR27","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/S2213-8587(24)00318-8","volume":"13","author":"N Stefan","year":"2025","unstructured":"Stefan, N., Yki-J\u00e4rvinen, H. & Neuschwander-Tetri, B. A. Metabolic dysfunction-associated steatotic liver disease: Heterogeneous pathomechanisms and effectiveness of metabolism-based treatment. Lancet Diabetes Endocrinol. 13(2), 134\u2013148 (2025).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"53503_CR28","doi-asserted-by":"publisher","DOI":"10.1093\/gastro\/goae029","volume":"12","author":"S Ciardullo","year":"2024","unstructured":"Ciardullo, S., Muraca, E., Vergani, M., Invernizzi, P. & Perseghin, G. Advancements in pharmacological treatment of NAFLD\/MASLD: A focus on metabolic and liver-targeted interventions. Gastroenterol. Rep. 12, goae029 (2024).","journal-title":"Gastroenterol. Rep."},{"issue":"4","key":"53503_CR29","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s40618-023-02216-y","volume":"47","author":"S Zhu","year":"2024","unstructured":"Zhu, S., Wu, Z., Wang, W., Wei, L. & Zhou, H. A revisit of drugs and potential therapeutic targets against non-alcoholic fatty liver disease: Learning from clinical trials. J. Endocrinol. Invest. 47(4), 761\u201376 (2024).","journal-title":"J. Endocrinol. Invest."},{"issue":"9","key":"53503_CR30","doi-asserted-by":"publisher","first-page":"e3003373","DOI":"10.1371\/journal.pbio.3003373","volume":"23","author":"L Bellassen","year":"2025","unstructured":"Bellassen, L. et al. The immune receptor SLAMF5 regulates myeloid-cell mediated neuroinflammation in multiple sclerosis. PLoS Biol. 23 (9), e3003373 (2025).","journal-title":"PLoS Biol."},{"issue":"17","key":"53503_CR31","doi-asserted-by":"publisher","first-page":"4633","DOI":"10.1182\/bloodadvances.2023011934","volume":"8","author":"JA van Bruggen","year":"2024","unstructured":"van Bruggen, J. A. et al. T-cell dysfunction in CLL is mediated through expression of Siglec-10 ligands CD24 and CD52 on CLL cells. Blood Adv. 8(17), 4633\u201346 (2024).","journal-title":"Blood Adv."},{"key":"53503_CR32","doi-asserted-by":"crossref","unstructured":"An, N., Bian, K. & Li, C. Alemtuzumab for haematological malignancies. Ann. Hematol. 104, 1\u201311 (2025).","DOI":"10.1007\/s00277-025-06344-8"},{"key":"53503_CR33","doi-asserted-by":"crossref","unstructured":"Geng, A. et al. Circulating monocytes upregulate CD52 and sustain innate immune function in cirrhosis unless acute decompensation emerges. J. Hepatol. 83, 146\u2013160 (2025).","DOI":"10.1016\/j.jhep.2024.12.031"},{"key":"53503_CR34","doi-asserted-by":"crossref","unstructured":"Wu, L. et al. Fatty acid-binding proteins in cancers. Int. J. Surg. 111, 1097 (2025).","DOI":"10.1097\/JS9.0000000000003049"},{"issue":"8","key":"53503_CR35","doi-asserted-by":"publisher","DOI":"10.1002\/mnfr.202300840","volume":"68","author":"FN Ba\u015far\u0131r Sivri","year":"2024","unstructured":"Ba\u015far\u0131r Sivri, F. N. & \u00c7ift\u00e7i, S. A new insight into fatty acid binding protein 4 mechanisms and therapeutic implications in obesity-associated diseases: A mini review. Mol. Nutr. Food Res. 68(8), 2300840 (2024).","journal-title":"Mol. Nutr. Food Res."},{"issue":"4","key":"53503_CR36","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1530\/EJE-10-1195","volume":"164","author":"X Terra","year":"2011","unstructured":"Terra, X. et al. FABP 4 is associated with inflammatory markers and metabolic syndrome in morbidly obese women. Eur. J. Endocrinol. 164(4), 539\u201347 (2011).","journal-title":"Eur. J. Endocrinol."},{"key":"53503_CR37","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.lfs.2019.03.046","volume":"224","author":"T Deng","year":"2019","unstructured":"Deng, T., Wang, Y., Wang, C. & Yan, H. FABP4 silencing ameliorates hypoxia reoxygenation injury through the attenuation of endoplasmic reticulum stress-mediated apoptosis by activating PI3K\/Akt pathway. Life Sci. 224, 149\u201356 (2019).","journal-title":"Life Sci."},{"issue":"1","key":"53503_CR38","doi-asserted-by":"publisher","first-page":"100975","DOI":"10.1016\/j.tranon.2020.100975","volume":"14","author":"N Attal","year":"2021","unstructured":"Attal, N., Sullivan, M. T., Girardi, C. A., Thompson, K. J. & McKillop, I. H. Fatty acid binding protein-4 promotes alcohol-dependent hepatosteatosis and hepatocellular carcinoma progression. Transl. Oncol. 14(1), 100975 (2021).","journal-title":"Transl. Oncol."},{"key":"53503_CR39","doi-asserted-by":"crossref","unstructured":"Xing, H. et al. FABP4 deficiency ameliorates alcoholic steatohepatitis in mice via inhibition of p53 signaling pathway. Sci. Rep. 14(1), 21135. (2024).","DOI":"10.1038\/s41598-024-71311-8"},{"issue":"6","key":"53503_CR40","doi-asserted-by":"publisher","first-page":"e0179737","DOI":"10.1371\/journal.pone.0179737","volume":"12","author":"R Nakamura","year":"2017","unstructured":"Nakamura, R. et al. Serum fatty acid-binding protein 4 (FABP4) concentration is associated with insulin resistance in peripheral tissues, a clinical study. PLoS One 12(6), e0179737 (2017).","journal-title":"PLoS One"},{"issue":"6","key":"53503_CR41","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1002\/cam4.1511","volume":"7","author":"CQ Zhong","year":"2018","unstructured":"Zhong, C. Q. et al. FABP4 suppresses proliferation and invasion of hepatocellular carcinoma cells and predicts a poor prognosis for hepatocellular carcinoma. Cancer Med. 7(6), 2629\u201340 (2018).","journal-title":"Cancer Med."},{"issue":"1","key":"53503_CR42","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/s41420-023-01744-z","volume":"9","author":"Z Wang","year":"2023","unstructured":"Wang, Z., Li, W., Chen, S. & Tang, X. X. Role of ADAM and ADAMTS proteases in pathological tissue remodeling. Cell Death Discov. 9(1), 447 (2023).","journal-title":"Cell Death Discov."},{"key":"53503_CR43","doi-asserted-by":"crossref","unstructured":"Rodriguez-Baena, F. J. et al. ADAMTS1 protease is required for a balanced immune cell repertoire and tumour inflammatory response. Sci. Rep. 8(1), 13103. (2018).","DOI":"10.1038\/s41598-018-31288-7"},{"key":"53503_CR44","doi-asserted-by":"crossref","unstructured":"Park, M. et al. ADAMTS-1: A novel target gene of an estrogen-induced transcription factor, EGR1, critical for embryo implantation in the mouse uterus. Cell Biosci. 11(1), 155. (2021).","DOI":"10.1186\/s13578-021-00672-8"},{"issue":"11","key":"53503_CR45","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1038\/cdd.2016.66","volume":"23","author":"S Chen","year":"2016","unstructured":"Chen, S. et al. The miR-181d-regulated metalloproteinase Adamts1 enzymatically impairs adipogenesis via ECM remodeling. Cell Death Differ. 23(11), 1778\u201391 (2016).","journal-title":"Cell Death Differ."},{"issue":"10","key":"53503_CR46","first-page":"4654","volume":"12","author":"J-C Hsu","year":"1992","unstructured":"Hsu, J-C., Bravo, R. & Taub, R. Interactions among LRF-1, JunB, c-Jun, and c-Fos define a regulatory program in the G1 phase of liver regeneration. Mol. Cell. Biol. 12 (10), 4654\u20134665 (1992).","journal-title":"Mol. Cell. Biol."},{"issue":"9","key":"53503_CR47","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1038\/s41418-018-0239-8","volume":"26","author":"I Schulien","year":"2019","unstructured":"Schulien, I. et al. The transcription factor c-Jun\/AP-1 promotes liver fibrosis during non-alcoholic steatohepatitis by regulating osteopontin expression. Cell Death Differ. 26(9), 1688\u20131699 (2019).","journal-title":"Cell Death Differ."},{"key":"53503_CR48","doi-asserted-by":"crossref","unstructured":"Ma, M., Xie, W. & Li, X. Identification of autophagy-related genes in the progression from non-alcoholic fatty liver to non-alcoholic steatohepatitis. Int. J. Gen. Med. 14, 3163\u20133176 (2021).","DOI":"10.2147\/IJGM.S317785"},{"issue":"7","key":"53503_CR49","doi-asserted-by":"publisher","first-page":"e67750","DOI":"10.1371\/journal.pone.0067750","volume":"8","author":"T Watanabe","year":"2013","unstructured":"Watanabe, T. et al. Protein kinase R modulates c-Fos and c-Jun signaling to promote proliferation of hepatocellular carcinoma with hepatitis C virus infection. PLoS. One 8(7), e67750 (2013).","journal-title":"PLoS. One"},{"issue":"8","key":"53503_CR50","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.humimm.2013.04.024","volume":"74","author":"LC Torres","year":"2013","unstructured":"Torres, L. C. et al. Disruption of the CREBBP gene and decreased expression of CREB, NF\u03baB p65, c-JUN, c-FOS, BCL2 and c-MYC suggest immune dysregulation. Hum. Immunol. 74(8), 911\u20135 (2013).","journal-title":"Hum. Immunol."},{"key":"53503_CR51","doi-asserted-by":"crossref","unstructured":"Zhao, Y., Yue, D. & Zou, Y. Orphan G protein-coupled receptor GPR88: Mapping its significance in central nervous system disorders. Mol. Neurobiol. 8, 1\u201311 (2025).","DOI":"10.1007\/s12035-025-04893-7"},{"issue":"1","key":"53503_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-10058-x","volume":"7","author":"J Lau","year":"2017","unstructured":"Lau, J., Farzi, A., Enriquez, R. F., Shi, Y.-C. & Herzog, H. GPR88 is a critical regulator of feeding and body composition in mice. Sci. Rep. 7(1), 9912 (2017).","journal-title":"Sci. Rep."},{"issue":"1","key":"53503_CR53","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-025-06490-7","volume":"23","author":"W Zhang","year":"2025","unstructured":"Zhang, W. et al. Identifying disease progression biomarkers in metabolic associated steatotic liver disease (MASLD) through weighted gene co-expression network analysis and machine learning. J. Transl. Med. 23(1), 472 (2025).","journal-title":"J. Transl. Med."},{"issue":"1","key":"53503_CR54","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1186\/s12967-023-04782-4","volume":"21","author":"Y Zhou","year":"2023","unstructured":"Zhou, Y., Xu, Z. & Liu, Z. Role of IL-33-ST2 pathway in regulating inflammation: Current evidence and future perspectives. J. Transl. Med. 21(1), 902 (2023).","journal-title":"J. Transl. Med."},{"key":"53503_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.meegid.2021.104983","volume":"94","author":"N Ma","year":"2021","unstructured":"Ma, N. et al. Genetic variants in IL33 and IL1RL1 genes confer susceptibility to HBV-related liver cirrhosis in Chinese Han population. Infect. Genet. Evol. 94, 104983 (2021).","journal-title":"Infect. Genet. Evol."},{"issue":"2","key":"53503_CR56","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s00011-019-01307-y","volume":"69","author":"GI Yu","year":"2020","unstructured":"Yu, G. I., Song, D. K. & Shin, D. H. Associations of IL1RAP and IL1RL1 gene polymorphisms with obesity and inflammation mediators. Inflamm. Res. 69 (2), 191\u2013202 (2020).","journal-title":"Inflamm. Res."},{"key":"53503_CR57","doi-asserted-by":"crossref","unstructured":"Morrow, G. B. & Mutch, N. J. (eds) Past, present, and future perspectives of plasminogen activator inhibitor 1 (PAI-1). Seminars in thrombosis and hemostasis (Thieme Medical Publishers, Inc, 2023).","DOI":"10.1055\/s-0042-1758791"},{"key":"53503_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2025.114828","volume":"158","author":"X Yang","year":"2025","unstructured":"Yang, X. et al. Targeting neutrophil extracellular traps: SERPINE1 and THBS1 as non-invasive biomarkers for early detection of liver fibrosis in metabolic dysfunction-associated steatotic liver disease. Int. Immunopharmacol. 158, 114828 (2025).","journal-title":"Int. Immunopharmacol."},{"issue":"3","key":"53503_CR59","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s12170-017-0536-7","volume":"11","author":"R Jin","year":"2017","unstructured":"Jin, R., Frediani, J. K., Holzberg, J. & Vos, M. B. Role of PAI-1 in pediatric obesity and nonalcoholic fatty liver disease. Curr. Cardiovasc. Risk Rep. 11 (3), 11 (2017).","journal-title":"Curr. Cardiovasc. Risk Rep."},{"issue":"07","key":"53503_CR60","first-page":"656","volume":"78","author":"I Juhan-Vague","year":"1997","unstructured":"Juhan-Vague, I. & Alessi, M. PAI-1, obesity, insulin resistance and risk of cardiovascular events. Thromb. Haemost. 78 (07), 656\u2013660 (1997).","journal-title":"Thromb. Haemost."},{"issue":"4","key":"53503_CR61","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/j.1365-2796.1990.tb00157.x","volume":"227","author":"K Landin","year":"1990","unstructured":"Landin, K., Tengborn, L. & Smith, U. Elevated fibrinogen and plasminogen activator inhibitor (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease. J. Intern. Med. 227(4), 273\u20138 (1990).","journal-title":"J. Intern. Med."},{"issue":"2","key":"53503_CR62","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1002\/jcp.22783","volume":"227","author":"AK Ghosh","year":"2012","unstructured":"Ghosh, A. K. & Vaughan, D. E. PAI-1 in tissue fibrosis. J. Cell. Physiol. 227(2), 493\u2013507 (2012).","journal-title":"J. Cell. Physiol."},{"key":"53503_CR63","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.638536","volume":"12","author":"LS Gutierrez","year":"2021","unstructured":"Gutierrez, L. S. & Gutierrez, J. Thrombospondin 1 in metabolic diseases. Front. Endocrinol. 12, 638536 (2021).","journal-title":"Front. Endocrinol."},{"issue":"3","key":"53503_CR64","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1002\/cbin.12126","volume":"48","author":"X Zhou","year":"2024","unstructured":"Zhou, X. et al. THBS1 promotes angiogenesis and accelerates ESCC malignant progression by the HIF-1\/VEGF signaling pathway. Cell Biol. Int. 48(3), 311\u201324 (2024).","journal-title":"Cell Biol. Int."},{"key":"53503_CR65","doi-asserted-by":"publisher","DOI":"10.1177\/15330338221085360","volume":"21","author":"A Jin","year":"2022","unstructured":"Jin, A., Zhou, J., Yu, P., Zhou, S. & Chang, C. High expression of THBS1 leads to a poor prognosis in papillary thyroid cancer and suppresses the anti-tumor immune microenvironment. Technol. Cancer Res. Treat. 21, 15330338221085360 (2022).","journal-title":"Technol. Cancer Res. Treat."},{"issue":"6","key":"53503_CR66","doi-asserted-by":"publisher","first-page":"e160745","DOI":"10.1172\/jci.insight.160745","volume":"8","author":"J Zhou","year":"2023","unstructured":"Zhou, J. et al. The long noncoding RNA THBS1-AS1 promotes cardiac fibroblast activation in cardiac fibrosis by regulating TGFBR1. JCI Insight 8(6), e160745 (2023).","journal-title":"JCI Insight"},{"issue":"1","key":"53503_CR67","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1159\/000527780","volume":"79","author":"M Li","year":"2023","unstructured":"Li, M., Liu, L., Kang, Y., Huang, S. & Xiao, Y. Circulating THBS1: A risk factor for nonalcoholic fatty liver disease in obese children. Ann. Nutr. Metab. 79(1), 16\u201328 (2023).","journal-title":"Ann. Nutr. Metab."},{"issue":"1","key":"53503_CR68","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s12916-024-03318-x","volume":"22","author":"HM Hassan","year":"2024","unstructured":"Hassan, H. M. et al. Thrombospondin 1 enhances systemic inflammation and disease severity in acute-on-chronic liver failure. BMC Med. 22 (1), 95 (2024).","journal-title":"BMC Med."},{"issue":"6","key":"53503_CR69","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1007\/s13577-021-00577-1","volume":"34","author":"Y Sun","year":"2021","unstructured":"Sun, Y. et al. MiR-222-3p induced by hepatitis B virus promotes the proliferation and inhibits apoptosis in hepatocellular carcinoma by upregulating THBS1. Hum. Cell 34(6), 1788\u201399 (2021).","journal-title":"Hum. Cell"},{"issue":"19","key":"53503_CR70","doi-asserted-by":"publisher","first-page":"20207","DOI":"10.1021\/acs.jmedchem.5c01256","volume":"68","author":"Y He","year":"2025","unstructured":"He, Y. et al. Discovery of potent and selective FABP4\/5 inhibitors with an isoquinolone scaffold as potential therapeutics for inflammation-related diseases. J. Med. Chem. 68(19), 20207\u201320227 (2025).","journal-title":"J. Med. Chem."},{"key":"53503_CR71","doi-asserted-by":"crossref","unstructured":"Guarnera, C., Bramanti, P. & Mazzon, E. Alemtuzumab: A review of efficacy and risks in the treatment of relapsing remitting multiple sclerosis. Ther. Clin. Risk Manag. 13, 871\u2013879 (2017).","DOI":"10.2147\/TCRM.S134398"},{"issue":"19","key":"53503_CR72","doi-asserted-by":"publisher","first-page":"2500136","DOI":"10.1002\/smll.202500136","volume":"21","author":"B Wang","year":"2025","unstructured":"Wang, B. et al. SERPINE1 facilitates metastasis in gastric cancer through anoikis resistance and tumor microenvironment remodeling. Small 21 (19), 2500136 (2025).","journal-title":"Small"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-53503-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-53503-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-53503-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T03:15:40Z","timestamp":1785122140000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-53503-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":72,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["53503"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-53503-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]},"assertion":[{"value":"8 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study has been approved by the Ethics Committee of Yueyang Hospital Affiliated to Hunan Normal University, approval number 2025016.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"23103"}}